"We Ain't Found Sh*t!" SPACEBALLS Actor Tim Russ Seems to Have Joined the Sequel — GeekTyrant
I'm very excited about this sequel, and it will bring back Bill Pullman and Rick Moranis as Lone Starr and Dark Helmet. They will be joined by Mel Brooks as Yogurt, Daphne Zuniga as Queen Vespa, Lewis Pullman, Keke Palmer, and Josh Gad.
The movie is described as a 'A Non-Prequel Non-Reboot Sequel Part Two' but with Reboot Elements Franchise Expansion Film.'
Josh Greenbaum ( Barb and Star Go to Vista Del Mar ) will direct, with Imagine's Brian Grazer and Jeb Brody producing alongside Gad, Brooks, and Greenbaum.
Gad also wrote the script along with Benji Samit and Dan Hernandez.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
21 minutes ago
- The Verge
Helldivers 2 is the first PlayStation-published Xbox game
Arrowhead Game Studios' Helldivers 2 will make the jump to the Xbox Series X and S consoles on August 26th, costing $39.99. This is the first PlayStation-published title to launch on Xbox. The title will ship with cross play between all platforms. The cooperative PvE third-person shooter was an unexpected hit when it first launched simultaneously on PlayStation 5 and PC in early 2023. It soared in popularity on Steam, where it earned an 'overwhelmingly positive' rating, which flipped to 'overwhelmingly negative' when Sony introduced (then swiftly reversed) a decision to require a PSN login for PC players. Xbox's press release makes no mention of a PSN login, so it likely won't be required here. Helldivers 2 is a gem of a game that's high on hijinx. What initially seems like a serious sci-fi title often gives way to funny, emergent moments, thanks in part to its Strategem system, which requires you to input complex button combos while facing down swarms of enemies. There are a variety of missions you can take on against aliens, robots, and a newer Illuminate species. And, since it's a live-service title, the lore and the stakes are always evolving (and the developers often troll players). It's a fun world to be immersed in, even if you're just grinding the free battle pass for weapon upgrades. My former Polygon colleague Cass Marshall wrote some incredible Helldivers 2 coverage, which have the power to convince just about anyone that they were missing out on a good time. I mean, just look at these headlines below.
Associated Press
25 minutes ago
- Associated Press
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax's GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique multi-antigen approach ATLANTA, GA - July 3, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today emphasized the urgent need for innovation in COVID-19 vaccination as the NB.1.8.1 variant - commonly known as 'Nimbus' - spreads rapidly across the globe. Nimbus, a highly transmissible Omicron subvariant classified by the World Health Organization as a 'Variant Under Monitoring,' is now dominant in multiple U.S. states and surging across Europe and Asia. Though not more severe, its rapid spread and potential for immune escape reflect an increasingly clear reality: COVID-19 is not going away, and it will continue to evolve. 'The emergence of the Nimbus variant is a stark reminder that we need 'smarter' vaccines, not just newer ones,' said David Dodd, Chairman and CEO of GeoVax. 'Our GEO-CM04S1 vaccine was designed for this purpose and is built to potentially provide broader and longer-lasting protection, especially for the immunocompromised patients most at risk.' GEO-CM04S1: Multi-Antigen Protection for the Immunocompromised Unlike mRNA vaccines that rely solely on the Spike protein, GEO-CM04S1 delivers both Spike (S) and Nucleocapsid (N) antigens, stimulating an immune response that includes not only an antibody response, but also robust T-cell activity. This is believed to be critical for cross-variant protection and extended durability, particularly in individuals with weakened immune systems. GEO-CM04S1 is currently being evaluated in two Phase 2 clinical trials, focused on populations at greatest risk from COVID-19 complications, including blood cancer patients scheduled to receive stem cell transplant therapy. In one of the ongoing Phase 2 trials, the mRNA control arm was discontinued due to poor immunogenicity with the remainder of the trial only including GEO-CM04S1 which surpassed the immunogenicity target, reinforcing the limitations of monovalent vaccines and the important value of a multi-antigen vaccine approach in such high-risk patient populations. 'There are more than 40 million immunocompromised individuals in the U.S. alone,' said Dodd. 'They are underserved by the current, FDA-approved vaccine options that deliver only an antibody response and require a better solution with both breadth and longevity of protection.' Public Vaccine Policy and Regulatory Changes Support Platform Diversification Recent guidance from the U.S. Food and Drug Administration (FDA) calls for diversified vaccine platforms and risk-based regulatory pathways. Additionally, the CDC's narrowed 2025–2026 booster recommendations - now focused on adults 65+ and immunocompromised individuals - closely mirror GeoVax's clinical strategy and target population. GEO-CM04S1 has been proposed under BARDA's Rapid Response Partnership Vehicle (RRPV) for surge manufacturing support and integration into long-term public health preparedness efforts. The proposal, 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines', was selected by the RRPV, pending funding availability. 'As public health moves toward more targeted, durable, and inclusive vaccination strategies, GEO-CM04S1 is positioned to deliver where first generation COVID-19 vaccines fall short,' Dodd added. In addition to targeting today's variants, GEO-CM04S1 is structurally designed to adapt to future mutations and serve as a platform for multi-pathogen preparedness. As part of GeoVax's broader MVA-based portfolio, the platform underpins vaccine candidates for Mpox, smallpox, and hemorrhagic fever viruses, offering scale and flexibility across infectious disease threats. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected]
Associated Press
26 minutes ago
- Associated Press
Maryland Vegan Eats Launches Inaugural Two-Day Vegan Summer Fest at Power Plant Live
Maryland Vegan Eats Debuts New Vegan Festival at Power Plant Live! for a Weekend of Plant-Based Delights and Entertainment US Vegan Climate ETF (VEGN) (NYSE:VEGN) 'We are thrilled to bring Maryland Vegan Eats Summer Fest to downtown Baltimore, providing a platform for both seasoned vegans and those curious about plant-based living to connect, learn, and indulge.'— Naijha Wright-Brown BALTIMORE, MD, UNITED STATES, July 3, 2025 / / -- Get ready to indulge in the vibrant world of plant-based cuisine at the inaugural Maryland Vegan Eats Summer Fest, taking place at Power Plant Live! in Baltimore's Inner Harbor on Saturday, August 23rd and Sunday, August 24th, 2025. This exciting event is proudly presented by Visit Maryland and organized by a coalition of local restaurant favorites, including The Land of Kush, Underground Pizza, Golden West Cafe, and Vegan SoulFest organizer and co-founder, Naijha Wright-Brown of Black Veg Society and Maryland Vegan Eats. 'We are thrilled to bring Maryland Vegan Eats Summer Fest to downtown Baltimore, providing a platform for both seasoned vegans and those curious about plant-based living to connect, learn, and indulge,' says Naijha Wright-Brown. 'This year's festival promises a fantastic experience with an incredible lineup of vendors, entertainment, and educational opportunities.' Maryland Vegan Eats and the Summer Fest aim to foster a greater appreciation for plant-based eating and its positive impact on health, animals, and the environment. The Maryland Vegan Eats Summer Fest promises a weekend full of delicious food, engaging activities, and entertainment for all ages. Attendees can explore a variety of food vendors showcasing the best in vegan cuisine, participate in cooking demonstrations, and enjoy live music and entertainment. Join in the weekend of fun and enjoy delicious food, engaging activities, and a celebration of the thriving vegan community. This festival is not just a celebration of plant-based living; it will also coincide with the bi-annual Maryland Vegan Restaurant Month, which runs from August 1st through August 31st, and highlights local establishments offering special plant-based dishes. The festival is currently seeking food vendors and restaurant participants for the vegan month. Event Details: Dates: Saturday, August 23rd, 2025 – Sunday, August 24th, 2025 Location: Power Plant Live! – 30 Market Place, Baltimore, MD 21202 Tickets & Info: In addition, on Saturday, September 6th at the Weinberg Y in Waverly located at 900 E 33rd Street, Baltimore, MD 21218, Black Veg Society and friends will feature the second annual Children's Veg Fest. This edutaining festival, presented by Dr. Bronner's, is dedicated to families and designed to educate and inspire children and young adults ages 5-24 about the benefits of plant-based eating, environmentalism, animal rights advocacy, and more. Parents can bring their entire family for fun activities, planting, cooking classes, and engaging performances that make learning about healthy eating enjoyable. The organizers are currently seeking young entrepreneurs to vend. For more information, go to Join these momentous occasions to celebrate the flavors and culture of plant-based living in Baltimore. Gather your friends and family for a weekend (or day) of fun, food, and community! Naijha Wright-Brown Black Veg Society +1 443-343-2834 [email protected] Visit us on social media: LinkedIn Instagram Facebook YouTube Other Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
